COMMUNIQUÉS West-GlobeNewswire
-
InStride Health’s New Peer-Reviewed Research Demonstrates Reductions in Caregiver Strain following Specialty Virtual Care for Families of Youth with Anxiety and OCD
07/07/2026 -
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
07/07/2026 -
Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas
07/07/2026 -
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
07/07/2026 -
CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types
07/07/2026 -
SS Innovations Subsidiary SSICRS Graduates Inaugural Cardiac Robotic Surgery Training Class
07/07/2026 -
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
07/07/2026 -
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
07/07/2026 -
New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
07/07/2026 -
Nu-Tek BioSciences Present Cell Nutrient Innovation, Raw Material Expertise at SIMB 2026
07/07/2026 -
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
07/07/2026 -
Cynet Joins Pax8 Marketplace to Help MSPs Manage the Modern Attack Path
07/07/2026 -
Presentation of New Clinical Data on Givinostat in Duchenne Muscular Dystrophy at ICNMD 2026
07/07/2026 -
Levicept Appoints Darlene Deptula-Hicks as CFO
07/07/2026 -
ImageneBio Appoints Matt Robbins as General Counsel
07/07/2026 -
Transactions in connection with share buy-back program
07/07/2026 -
Aclarion Announces Texas Spine Care Center as New CLARITY Site
07/07/2026 -
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
07/07/2026 -
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
07/07/2026
Pages